Parametric Portfolio Associates LLC lessened its holdings in Bruker Co. (NASDAQ:BRKR) by 0.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 253,801 shares of the medical research company’s stock after selling 1,204 shares during the period. Parametric Portfolio Associates LLC’s holdings in Bruker were worth $9,756,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in BRKR. Cambiar Investors LLC grew its stake in Bruker by 54.9% during the first quarter. Cambiar Investors LLC now owns 210,437 shares of the medical research company’s stock worth $8,089,000 after buying an additional 74,580 shares during the period. Great West Life Assurance Co. Can grew its stake in Bruker by 14.0% during the first quarter. Great West Life Assurance Co. Can now owns 14,288 shares of the medical research company’s stock worth $547,000 after buying an additional 1,751 shares during the period. New York State Common Retirement Fund grew its stake in Bruker by 0.3% during the first quarter. New York State Common Retirement Fund now owns 444,726 shares of the medical research company’s stock worth $17,095,000 after buying an additional 1,195 shares during the period. MERIAN GLOBAL INVESTORS UK Ltd grew its stake in Bruker by 14.8% during the first quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 963,488 shares of the medical research company’s stock worth $37,036,000 after buying an additional 124,247 shares during the period. Finally, Raymond James & Associates grew its stake in Bruker by 2.8% during the first quarter. Raymond James & Associates now owns 15,795 shares of the medical research company’s stock worth $607,000 after buying an additional 425 shares during the period. 66.74% of the stock is currently owned by institutional investors.
In other Bruker news, Director Marc A. Kastner sold 1,374 shares of the stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $41.79, for a total transaction of $57,419.46. Following the transaction, the director now directly owns 10,811 shares in the company, valued at approximately $451,791.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Frank H. Laukien sold 400,000 shares of the stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $41.48, for a total transaction of $16,592,000.00. Following the transaction, the chief executive officer now owns 37,991,030 shares in the company, valued at $1,575,867,924.40. The disclosure for this sale can be found here. Insiders sold 801,374 shares of company stock valued at $33,241,419 over the last 90 days. Insiders own 26.50% of the company’s stock.
Shares of BRKR stock opened at $45.77 on Friday. The firm has a market capitalization of $7.28 billion, a PE ratio of 32.69, a PEG ratio of 2.35 and a beta of 1.26. The company has a quick ratio of 1.27, a current ratio of 2.12 and a debt-to-equity ratio of 0.42. Bruker Co. has a twelve month low of $26.10 and a twelve month high of $46.74.
Bruker (NASDAQ:BRKR) last announced its earnings results on Thursday, May 2nd. The medical research company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.04. The business had revenue of $461.40 million during the quarter, compared to the consensus estimate of $450.46 million. Bruker had a net margin of 9.53% and a return on equity of 26.28%. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.24 earnings per share. On average, research analysts predict that Bruker Co. will post 1.62 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 21st. Stockholders of record on Monday, June 3rd will be paid a $0.04 dividend. The ex-dividend date of this dividend is Friday, May 31st. This represents a $0.16 annualized dividend and a dividend yield of 0.35%. Bruker’s dividend payout ratio (DPR) is presently 11.43%.
BRKR has been the subject of several research reports. Needham & Company LLC reiterated a “strong-buy” rating and set a $46.00 price objective (up from $39.00) on shares of Bruker in a research note on Monday, May 6th. Deutsche Bank upgraded shares of Bruker from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $40.00 to $50.00 in a research note on Friday, April 12th. BidaskClub upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research note on Wednesday, June 5th. UBS Group upgraded shares of Bruker from a “sell” rating to a “neutral” rating and set a $43.00 price objective for the company in a research note on Friday, May 3rd. Finally, Leerink Swann upgraded shares of Bruker from a “market perform” rating to an “outperform” rating in a research note on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Bruker has an average rating of “Buy” and a consensus price target of $43.71.
TRADEMARK VIOLATION WARNING: This piece was published by Modern Readers and is the property of of Modern Readers. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.modernreaders.com/news/2019/06/14/parametric-portfolio-associates-llc-sells-1204-shares-of-bruker-co-nasdaqbrkr.html.
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
See Also: Price to Earnings Ratio (PE)
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR).
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.